InvestorsHub Logo
Followers 53
Posts 1782
Boards Moderated 0
Alias Born 03/22/2015

Re: namtae post# 312078

Tuesday, 03/19/2019 9:51:37 AM

Tuesday, March 19, 2019 9:51:37 AM

Post# of 402252
Nobody who has done any DD says that.




ELTP wont benefit from Isradipine approval for PD?

Here's the case being made:


Quote from numbersarefun:

I do not think Elite Pharmaceuticals has ever said anything. The hype is that ELTP would benefit from isradipine for parkinson's research.

According to parkinson-study-group.org homepage, "The PSG has partnered with numerous pharmaceutical companies and the National Institutes of Health (NIH) in bringing new drugs for Parkinson disease to the market including pramipexole, entacapone, rotigotine and rasagiline." Those are expensive drugs called Mirapex, Comtan, Neupro, and Azilect.

Isradipine for parkinson would most likely be manufactured and marketed, under a brand name, by a pharmaceutical. That is probably years away, assuming it works. Don't you need two Phase 3 studies to file an NDA?

Also, isradipine for parkinson has a pending patent by the inventor. I assume the patent holder would license it to some pharmaceutical to gain financially from the research.







My response to numbersarefun:


Which fact about ELTP and isradipine do you not believe? Is it that Elite is one of two companies that currently manufactures isradipine? Is it that isradipine for Parkinson's Disease passed a Phase 2 safety study, called STEADYPD-II? Do you dispute that a Phase 3 efficacy study of isradipine for Parkinson's (STEADYPD-III) has been done and the results will be released in early May?







Never got a reply.





Call on God but row away from the rocks.

-Hunter S. Thompson

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News